Literature DB >> 20876189

A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France.

F Sahajian1, F Bailly, P Vanhems, B Fantino, C Vannier-Nitenberg, J Fabry, C Trepo.   

Abstract

BACKGROUND: We compared the efficacy of two viral hepatitis B and C (VHBC) screening strategies, relative to no intervention, among underprivileged people (UP) living in shelters in the Lyon area.
METHODS: Eighteen of 37 shelters were randomly sampled after stratification based on the accommodation capacity and the screening centres/shelters distance. Through randomization, the S0 strategy (no intervention), the S1 strategy [group information (GI) and referral for screening] and the S2 strategy (GI and in situ screening) were each applied in six shelters. A standardized questionnaire was offered to each participant. Follow-up of positive cases was organized via the reference centre of VHBC of Lyon.
RESULTS: The screening completion rate (SCR) among 1276 included subjects in S0, S1 and S2 was 1.5, 42.8 and 59.7%, respectively (P < 10(-6)). This rate was higher in S2 regardless of the sociodemographic variable considered. Odds ratios (OR) of screening completion (SC) was significantly higher in S1 versus S0, OR = 49.8 [95% confidence interval (CI): 26.1-102.1], in S2 versus S0, OR = 98.5 (95% CI: 51.9-200.8) and in S2 versus S1, OR = 2.0 (95% CI: 1.3-2.9). Age, country of birth and professional inactivity were independently associated with SC.
CONCLUSIONS: Health authorities must ensure widespread screening of UP, which is more effective when conducted in shelters than in screening centres.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876189     DOI: 10.1093/pubmed/fdq071

Source DB:  PubMed          Journal:  J Public Health (Oxf)        ISSN: 1741-3842            Impact factor:   2.341


  7 in total

Review 1.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

2.  A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.

Authors:  Andrew Radley; Karen Melville; Jan Tait; Brian Stephens; Josie M M Evans; John F Dillon
Journal:  Frontline Gastroenterol       Date:  2017-01-06

3.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

Review 4.  Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.

Authors:  Esther Jane Aspinall; Joseph Samuel Doyle; Stephen Corson; Margaret Elena Hellard; David Hunt; David Goldberg; Tim Nguyen; Yngve Falck-Ytter; Rebecca Lynn Morgan; Bryce Smith; Mark Stoove; Stefan Zbyszko Wiktor; Sharon Hutchinson
Journal:  Eur J Epidemiol       Date:  2014-11-11       Impact factor: 8.082

Review 5.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

6.  Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Authors:  Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi
Journal:  J Viral Hepat       Date:  2019-08-16       Impact factor: 3.728

7.  Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.

Authors:  Jisoo A Kwon; Gregory J Dore; Behzad Hajarizadeh; Maryam Alavi; Heather Valerio; Jason Grebely; Rebecca Guy; Richard T Gray
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.